Spyre Therapeutics (SYRE) Receivables - Net (2015 - 2024)
Spyre Therapeutics' (SYRE) quarterly Receivables - Net came in at $5.9 million in Q3 2024, little changed on a QoQ basis from $5.9 million in Q2 2024.
Spyre Therapeutics (SYRE) Receivables - Net (2015 - 2024) Analysis & Trends
Spyre Therapeutics (SYRE) has 6 years of Receivables - Net data on file, last reported at $5.9 million in Q3 2024.
- Quarterly Receivables - Net changed N/A year-over-year to $5.9 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $5.9 million (changed N/A YoY) and the FY2017 annual result came in at $3.1 million, up 153.33% from the prior year.
- Receivables - Net steadied at $5.9 million in Q3 2024, from $5.9 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $21.5 million in Q1 2021 to a low of $5.9 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 5.90 Mn |
| Sep 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Jun 30, 2024 | 5.90 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Sep 30, 2018 | 2.42 Mn |
| Sep 30, 2018 | 2.42 Mn |
| Jun 30, 2018 | 4.28 Mn |
| Jun 30, 2018 | 4.28 Mn |
| Mar 31, 2018 | 3.37 Mn |
| Mar 31, 2018 | 3.37 Mn |
| Dec 31, 2017 | 3.08 Mn |
| Dec 31, 2017 | 3.08 Mn |
| Sep 30, 2017 | 2.45 Mn |
| Sep 30, 2017 | 2.45 Mn |
| Jun 30, 2017 | 1.21 Mn |
| Jun 30, 2017 | 1.21 Mn |
| Mar 31, 2017 | 981,000.00 |
| Mar 31, 2017 | 981,000.00 |